Sign the pledge! @Jossoloan talks #hepC elimination and how GPs can pledge to raise the number of people treated in… https://t.co/y5HvkaqE49
ASHM Report Back
Clinical posts from members and guests of the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM) from various international medical and scientific conferences on HIV, AIDS, viral hepatitis, and sexual health.
B/F/TAF vs DTG/F/TAF 48 week data. Non inferiority
A late breaker poster was presented Tuesday showing the 48 weeks data comparing Bictegravir co-formulated with FTC/TDF in a fixed dose combination (B/F/TAF) vs. DTG/F/TAF in treatment naïve HIV-1 positive adults. The study is phase 3 multi-centered RCT with a primary endpoint of HIV-1 RNA < 50 copies /mL at 48 weeks, powered for non-inferiority.
B/F/TAF was safe, well tolerated and non-inferior to DTG/F/TAF in treatment naïve adults. Discontinuations due to adverse events were uncommon in both arms . There was no evidence of treatment-emergent resistance to study medication. Interestingly there was less of a decrease in the e GFR observed in the B/F/TAF participants. No difference observed in lipids.
Tagged in:
2017 IAS Conference
Trackback URL for this blog entry.
